Polytrim

Shigellosis, Nocardiosis, Brucellosis + 16 more

Treatment

17 FDA approvals

16 Active Studies for Polytrim

What is Polytrim

Trimethoprim

The Generic name of this drug

Treatment Summary

Polymyxin B is an antibiotic used to treat infections caused by certain types of bacteria. It is used to treat infections in the urinary tract, meninges, and bloodstream caused by _Pseudomonas aeruginosa_, a type of bacteria. Polymyxin B has strong effects on cell membranes and can be neurotoxic and nephrotoxic, so it is not typically used as the first line of treatment.

Septra DS

is the brand name

image of different drug pills on a surface

Polytrim Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Septra DS

Trimethoprim

1973

343

Approved as Treatment by the FDA

Trimethoprim, also called Septra DS, is approved by the FDA for 17 uses including Cholera and susceptible Enteritis infectious caused by Shigella sonnei .

Cholera

Used to treat susceptible Cholera in combination with Sulfamethoxazole

susceptible Enteritis infectious caused by Shigella sonnei

Used to treat susceptible Enteritis infectious caused by Shigella sonnei in combination with Sulfamethoxazole

Fluid replacement therapy

Used to treat Fluid replacement therapy in combination with Sulfamethoxazole

Urinary tract infection

Used to treat Urinary Tract Infection caused by susceptible bacteria in combination with Sulfamethoxazole

Nocardiosis

Used to treat Nocardiosis in combination with Sulfamethoxazole

Pneumonia, Pneumocystis

Used to treat Pneumocystis Jirovecii Pneumonia in combination with Sulfamethoxazole

Genus Pneumocystis

Used to treat risk of Pneumocystis jiroveci pneumonia (PCP) in combination with Sulfamethoxazole

Otitis Media

Used to treat Acute Otitis Media caused by susceptible bacteria in combination with Sulfamethoxazole

Brucellosis

Used to treat Brucellosis in combination with Rifampicin

Electrolyte replacement

Used to treat Electrolyte replacement in combination with Sulfamethoxazole

Pneumocystis Jirovecii Pneumonia

Used to treat Pneumocystis Jirovecii Pneumonia in combination with Sulfamethoxazole

Shigellosis

Used to treat Dysentery, Bacillary in combination with Sulfamethoxazole

Bronchitis

Used to treat Acute Exacerbation of Chronic Bronchitis (AECB) caused by susceptible bacteria in combination with Sulfamethoxazole

Diarrhea

Used to treat susceptible Travelers' Diarrhea caused by Enterotoxigenic E. Coli (ETEC) Infection in combination with Sulfamethoxazole

susceptible Enteritis infectious caused by Shigella flexneri

Used to treat susceptible Enteritis infectious caused by Shigella flexneri in combination with Sulfamethoxazole

Brucellosis

Used to treat Brucellosis in combination with Rifampicin

Immunocompromised

Used to treat Immunocompromised in combination with Sulfamethoxazole

Effectiveness

How Polytrim Affects Patients

Polymyxin B is an antibiotic that targets and destroys Gram-negative bacteria. It is usually given through injection or other routes and is not changed by metabolic processes in the body. It is used to treat urinary tract, meningeal, and blood stream infections caused by susceptible Gram-negative bacteria.

How Polytrim works in the body

Polymyxin B is an antibiotic used to treat infections caused by certain types of bacteria. It works by binding to and destabilizing the outer membrane of the bacteria, causing it to leak and die. Polymyxin B also binds to and neutralizes molecules released by the bacteria, and it inhibits the enzymes used by the bacteria for respiration. It is active against some Gram negative bacteria, but not Gram positive bacteria or anaerobic bacteria.

When to interrupt dosage

The prescribed dosage of Polytrim is dependent upon the diagnosed condition, such as Urinary tract infection, Acute Otitis Media (AOM) and Otorrhoea. The amount of dosage may differ as per the method of administration (e.g. Topical or Suspension / drops - Auricular (otic)) detailed in the accompanying table.

Condition

Dosage

Administration

Pneumonia, Pneumocystis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Conjunctivitis, Bacterial

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Brucellosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Immunocompromised

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Nocardiosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Urinary tract infection

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

bacterial blepharitis caused by susceptible bacteria

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Urinary tract infection

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Diarrhea

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Shigellosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Electrolyte replacement

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Fluid replacement therapy

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Genus Pneumocystis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Bacterial conjunctivitis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Bronchitis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

susceptible Enteritis infectious caused by Shigella flexneri

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

susceptible Enteritis infectious caused by Shigella sonnei

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Otitis Media

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Cholera

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Injection, solution, concentrate - Intravenous

Warnings

Polytrim has two contraindications, so it should not be employed in combination with the circumstances laid out in the subsequent table.

Polytrim Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Trimethoprim may interact with Pulse Frequency

Purpura, Thrombocytopenic, Idiopathic

Do Not Combine

hepatic damage

Do Not Combine

Megaloblastic anemia caused by Folate deficiency

Do Not Combine

unable to monitor renal function

Do Not Combine

Disease

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Trimethoprim may interact with Pulse Frequency

There are 20 known major drug interactions with Polytrim.

Common Polytrim Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Trimethoprim.

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Trimethoprim.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Trimethoprim.

Cisplatin

Major

The serum concentration of Cisplatin can be increased when it is combined with Trimethoprim.

Clofarabine

Major

The serum concentration of Clofarabine can be increased when it is combined with Trimethoprim.

Polytrim Toxicity & Overdose Risk

Taking too much polymyxin B can result in kidney damage, breathing problems, and muscle weakness. Symptoms of an overdose may also include confusion, vertigo, slurred speech, and vision problems. Treatment for overdose can involve stopping the drug and providing supportive care, as well as taking medications like mannitol to help clear the kidneys. Polymyxin B should not be used during pregnancy, while breastfeeding, or with pediatric and elderly patients, as it can be dangerous.

image of a doctor in a lab doing drug, clinical research

Polytrim Novel Uses: Which Conditions Have a Clinical Trial Featuring Polytrim?

46 active clinical trials are currently looking into the possibility of using Polytrim to mitigate Klebsiella, Otorrhoea and Pseudomonas Infections.

Condition

Clinical Trials

Trial Phases

Urinary tract infection

0 Actively Recruiting

Bacterial conjunctivitis

0 Actively Recruiting

Bronchitis

0 Actively Recruiting

Nocardiosis

0 Actively Recruiting

Shigellosis

0 Actively Recruiting

Brucellosis

0 Actively Recruiting

bacterial blepharitis caused by susceptible bacteria

0 Actively Recruiting

Immunocompromised

2 Actively Recruiting

Phase 1, Not Applicable

Otitis Media

0 Actively Recruiting

Genus Pneumocystis

0 Actively Recruiting

Conjunctivitis, Bacterial

0 Actively Recruiting

Fluid replacement therapy

0 Actively Recruiting

Cholera

0 Actively Recruiting

Urinary tract infection

0 Actively Recruiting

susceptible Enteritis infectious caused by Shigella sonnei

0 Actively Recruiting

Pneumonia, Pneumocystis

2 Actively Recruiting

Phase 3, Phase 4

susceptible Enteritis infectious caused by Shigella flexneri

0 Actively Recruiting

Electrolyte replacement

0 Actively Recruiting

Diarrhea

12 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 1

Polytrim Reviews: What are patients saying about Polytrim?

5

Patient Review

2/15/2009

Polytrim for Pink Eye from Bacterial Infection

We've had to use this treatment twice now, and both times it's worked within hours. No noticeable side effects either time.

4.7

Patient Review

4/19/2019

Polytrim for Pink Eye from Bacterial Infection

After just two days, this medication cleared up my problem. However, it also caused some serious itching.

4.7

Patient Review

9/13/2010

Polytrim for Pink Eye from Bacterial Infection

This works great, though it can be tough to administer to a young child or infant.

4

Patient Review

7/14/2015

Polytrim for Pink Eye from Bacterial Infection

I received this medication late on a Saturday night from urgent care and took one dose before bed. By the next morning, my eye was significantly improved; by that afternoon, it was 75% better. I'm currently on the third day of treatment (four doses in) and don't even remember I have pink eye most of time. The only issue is the itchiness I experience for half an hour to 45 minutes after taking the drops -- which, per the instructions, are two drops four times a day. Here's hoping I can make it through all seven days without causing myself more irritation!

4

Patient Review

11/25/2015

Polytrim for Pink Eye from Bacterial Infection

These eye drops were much more effective than the others I've tried, and it only took three days to clear up my pink eye. My doctor said to use them for 10 days regardless, but I think the duration could be shorter for other people. They have a cool feeling when applied, with a slight sting if you're not used to it.

2.3

Patient Review

10/26/2017

Polytrim for Inflammation of Eyelid Edges and the Lining of the Eye

This didn't help me unfortunately.

2

Patient Review

11/4/2015

Polytrim for Pink Eye from Bacterial Infection

After using Polytrim for two days with no results, I went back to urgent care. They told me that the medicine wasn't right for me and prescribed steroids and tobramycin drops instead. The swelling has gone down but the pink eye is doing much better after two days.

2

Patient Review

4/22/2009

Polytrim for Pink Eye from Bacterial Infection

Polytrim unfortunately didn't work for me, though I hear it does the trick for other people.

1.7

Patient Review

6/21/2012

Polytrim for Pink Eye from Bacterial Infection

These eyedrops were unfortunately very itchy and not worth the relief they provided.

Patient Q&A Section about polytrim

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of antibiotic is Polytrim?

"Polytrim consists of polymyxin B and trimethoprim, two antibiotics which work together to kill bacteria. Polymixin B works by damaging the bacteria's protective covering, while trimethoprim inhibits the bacteria's ability to obtain nutrients, ultimately leading to its death."

Answered by AI

Do you need a prescription for Polytrim?

"Polytrim is a prescription medication used to treat the symptoms of Bacterial Conjunctivitis. Polytrim may be used alone or in combination with other medications. Polytrim belongs to a class of drugs called Antibiotic Ophthalmic Combinations."

Answered by AI

Does Polytrim treat pink eye?

"Polytrim is an antibiotic eye drop used to treat bacterial infections of the eye, including conjunctivitis and conjunctivitis combined with an eyelid infection."

Answered by AI

What is Polytrim used to treat?

"This medication is used to treat bacterial infections of the eye. Polymyxin B works by killing the bacteria. Trimethoprim works by stopping the growth of the bacteria."

Answered by AI

Clinical Trials for Polytrim

Image of McGill university Health Centre (Royal victoria Hospital and Montreal General Hospital in Montreal, Canada.

Systemic Corticosteroids for Pneumocystis Pneumonia

18+
All Sexes
Montreal, Canada

The HOW LONG trial is an international, multicenter, Phase IV randomized clinical trial evaluating the optimal duration of adjunctive systemic corticosteroids in immunocompromised adults with severe Pneumocystis jirovecii pneumonia (PCP) who demonstrate early clinical recovery. Participants who no longer require supplemental oxygen by day 10 of corticosteroid therapy are randomized to discontinue corticosteroids at day 10 (or hospital discharge, if earlier) versus continue corticosteroids for a total of 21 days. The trial assesses whether earlier discontinuation reduces steroid-related complications while maintaining clinical outcomes.

Phase 4
Waitlist Available

McGill university Health Centre (Royal victoria Hospital and Montreal General Hospital

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Have you considered Polytrim clinical trials?

We made a collection of clinical trials featuring Polytrim, we think they might fit your search criteria.
Go to Trials
Image of University of Maryland, School of Medicine, Center for Vaccine Development and Global Health in Baltimore, United States.

Vaccine for E. coli Infections

18 - 49
All Sexes
Baltimore, MD

The study is designed to evaluate the safety, immunogenicity, and efficacy of the intramuscular administration of a CS6 based vaccine (CssBA) against ETEC co-administered with double mutant labile toxin (dmLT) in preventing moderate-severe diarrhea (MSD) following challenge with ETEC strain B7A in healthy adults. Approximately 72 adult participants, divided into 4 cohorts of 18, will be randomized 1:1 to receive vaccine (45 micrograms CssBA with 0.5 micrograms dmLT) or placebo (normal saline) on an outpatient basis. All participants will receive 3 intramuscular (IM) doses of vaccine or placebo at 3-week intervals (days 1, 22 and 43). Following vaccination, participants will be followed as outpatients for safety using a memory aid from the time of each vaccination through 7 days post each vaccination. Approximately 28 days (plus or minus 1 day) after receipt of the 3rd dose of study agent, participants meeting challenge criteria will be admitted to an inpatient unit and be administered an oral dose of 1 x 10\^10 cfu (colony-forming unit) of ETEC strain B7A. Five days after challenge, participants will be treated with ciprofloxacin, except in cases of known allergy or intolerance. Participants will be discharged from the inpatient unit when they have completed their 3-day antibiotic course and are able to care for themselves. After discharge from the inpatient unit, participants will return for clinic visits and have a phone visit to provide any updates on medication, medical history and AE/SAEs. The primary objectives are: 1) Estimate CssBA+dmLT efficacy in preventing moderate-severe diarrhea (MSD) following challenge with ETEC strain B7A in healthy adults. 2) Evaluate the safety of intramuscular injection of CssBA+dmLT.

Phase 2
Waitlist Available

University of Maryland, School of Medicine, Center for Vaccine Development and Global Health (+1 Sites)

Have you considered Polytrim clinical trials?

We made a collection of clinical trials featuring Polytrim, we think they might fit your search criteria.
Go to Trials
Image of McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital) in Montreal, Canada.

Low-Dose Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia

18 - 100
All Sexes
Montreal, Canada

Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection of immunocompromised hosts which causes in significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of TMP, is associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure occurring among 20-60% of patients. The frequency of adverse events increases in a dose dependent manner and commonly limits the use of TMP-SMX. Reduced treatment doses of TMP-SMX for PJP reduced ADEs without mortality differences in a recent meta-analysis of observational studies. We therefore propose a Phase III randomized, placebo-controlled trial to directly compare the efficacy and safety of low dose (10 mg/kg/day of TMP) compared to the standard-of-care (15 mg/kg/day) among patients with PJP for the primary outcome of death, new mechanical ventilation, and change of treatment.

Phase 3
Waitlist Available

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)

Emily G McDonald, MD MSc

Have you considered Polytrim clinical trials?

We made a collection of clinical trials featuring Polytrim, we think they might fit your search criteria.
Go to Trials